Howard H. Bailey
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
600 Highland Avenue K4/6 CSC
Madison
WI 53792
USA
Name/email consistency: high
- Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Bailey, H.H., Attia, S., Love, R.R., Fass, T., Chappell, R., Tutsch, K., Harris, L., Jumonville, A., Hansen, R., Shapiro, G.R., Stewart, J.A. Cancer Chemother. Pharmacol. (2008)
- A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Bailey, H.H., Wilding, G., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Simon, K., Marnocha, R., Holstein, S.A., Stewart, J., Lewis, K.A., Hohl, R.J. Cancer Chemother. Pharmacol. (2004)
- A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Bailey, H.H., Levy, D., Harris, L.S., Schink, J.C., Foss, F., Beatty, P., Wadler, S. Gynecol. Oncol. (2002)
- L-S,R-buthionine sulfoximine: historical development and clinical issues. Bailey, H.H. Chem. Biol. Interact. (1998)
- Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Bailey, H.H., Ripple, G., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R.T., Wilding, G. J. Natl. Cancer Inst. (1997)